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Abstract.Objective: This study aimed to investigate the role of genetic biomarkers in assessing risk for the eventual development
of type 2 diabetes mellitus (T2DM).
Methods: Three Maltese women with a history of previous severe GDM and with apparent similar clinical risk factors
underwent anthropomorphic and metabolic reassessment 4–7 years post-partum. They were further genotyped for four specific
genetic single nucleotide polymorphisms (SNPs) using the qPCR technique for the alleles of SLC2A2 (rs5393A/C), FTO
(rs9939609A/T), PCK (rs2071023C/G) and CDKAL1 (rs10946398A/C).
Results:While the previous obstetric history of all the cases was similar, the biological status was characterized by an increasing
degree of obesity correlating to increasing severity of current carbohydrate intolerance. Genotyping showed that all the tested
SNPs were homozygous mutant in the T2DM woman and heterozygous in the impaired glucose tolerance woman. The woman
with normal glucose tolerance was shown to be wild type for SLC2A2 (rs5393A/C).
Conclusions: There appeared to be an interrelationship between eventual severity of carbohydrate metabolism abnormalities
and the genetic allele status. It would appear that the specific allele-scoring can be used to identify further the potential risk of
developing T2DM.
Keywords: Type 2 diabetes mellitus, risk factors, previous gestational diabetes mellitus, single nucleotide polymorphism, specific
allele-scoring
1. Introduction
In every society there are communities, families and individuals whose chance of future illness, acci-
dent or untimely death are greater than those of others. Special vulnerability to illness results from the
possession of a number of interacting characteristics that range from genetic to biosocial factors. The
ability to measure some of these risks provides a means with which to allow health providers to apply
a preventive aspect of health care especially in medical conditions that initially have an insidious onset
before full-blown clinical presentation. One such condition is the metabolic syndrome with its wide spec-
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trum of clinical features that include Type 2 DM [T2DM], hypertension, and lipid profile abnormalities.
Unfortunately, assumed risk factors based on “historic” and biological characteristics have been shown
to have poor sensitivity and specificity [1].
The Maltese population has been repeatedly shown to have a high prevalence of T2DM that appears
to be contributed to in part by environmental [2] and in part by genetic factors [3]. The present study
attempts to investigate the possible role of genetic factors being used as supplementary markers for risk
assessment in the development of T2DM. The identification of effective supplementary markers would
hopefully strengthen the sensitivity and specificity of the currently identified risk factors and enable
targeting of dedicated health services to those individuals who really need them.
2. Methods
Three women aged 39–40 years identified from their obstetric history as being at an increased risk
of their eventually developing T2DM were investigated 4–7 years after their pregnancy with a 75-gram
oral glucose tolerance test and lipid profile to identify their current metabolic status. The metabolic
profile of these three women varied from T2DM to normal glucose tolerance [NGT]. The women were
further assessed to identify the presence of other current risk factors such as obesity and hypertension.
In addition, blood was collected to determine the presence of variations in a series of alleles of genes, in
terms of single nucleotide polymorphism (SNPs) that have previously been identified from the published
literature and past studies carried out in the present population to be relevant in the involvement in
various biological pathways of glucose homeostasis and inflammatory responses, conferring a strong
susceptibility to T2DM [3]. The selected specific protein coding genes included: SLC2A2 (Solute carrier
family 2-facilitated glucose transporter-member 2) gene, FTO (Fat mass and obesity associated) gene,
PCK (phosphoenolpyruvate carboxykinase) gene and CDKAL1 (CDK5 regulatory subunit associated
protein 1-like 1). The tested specific correspondent SNPs of these genes included: SLC2A2 (rs5393 A/C),
FTO (rs9939609 A/T), PCK (rs2071023 C/G) and CDKAL1 (rs10946398 A/C). The latter methodology
as been previously detailed [3]. Ethical approval for the study was obtained from the Ethical Committee
of the University of Malta. The women gave their signed consent for the study.
3. Results
The previous obstetric history and the current biological status of the three cases are summarized in
Table 1. It would appear that the previous obstetric history is similar in all the three individuals, with
the less severe cases actually delivering macrosomic infants in contrast to the individual with T2DM.
The anthropomorphic characteristics are markedly different, these differences dating to the gestational
period. The biological status of the individuals is characterized by an increasing degree of obesity, as
defined by the Body Mass Index (BMI) and waist circumference, with increasing severity of carbohydrate
intolerance.
In contrast to the obstetric history and biological factors, the genotyping characteristics of the selected
SNPs were however markedly different between the three probands. The case with T2DM has been noted
to have simultaneous homozygous mutations in four of the tested SNP genes. In contrast, the case with
IGT only showed heterozygosity for the four SNP genes; while the case with normal glucose tolerance
only showed heterozygosity for two SNP genes, but had in addition one mutant and one wild type SNP
gene (Table 2).
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Table 1
Clinical risk factors in the three women with previous GDM
Risk factor Case 1 Case 2 Case 3
Current carbohydrate metabolic status Normal glucose Impaired glucose Type 2 diabetes
tolerance tolerance mellitus
Pregnancy data
Past history of severe GDM [defined as a
2-hour post-glucose load of ≥11.0 mmol/l] Yes Yes Yes
1. age at diagnosis (years) 31 34 36
Age now (duration after first diagnosis in years) 38 (7) 40 (6) 40 (4)
H/O gestational hypertension No No No
Family history of
Diabetes No Yes Yes
Obesity No Yes Yes
BMI during last pregnancy [kg/m2] 20 31 36
Gestational age at delivery [weeks] 39 40 38
Infant birth weight [gm] 4220 4440 3020
Infant head circumference [cm] 36 37 33
Neonatal complications Hypoglycaemia Nil Nil
Current biological data
Current lipid profile
Total Cholesterol mmol/l 6.20 5.02 5.70
LDL mmol/l 4.15 2.89 4.04
HDL mmol/l 1.46 1.58 1.07
S.TG mmol/l 1.30 1.20 1.30
Current age [years] 39 41 40
Parity + miscarriages 3 + 0 2 + 0 2 + 1
Current BMI [kg/m2] 23.7 26.3 37.3
Current waist circumference [cm] 81 98 112
Waist hip ratio 0.87 0.94 0.98
Current blood pressure reading [mmHg] 110/70 120/80 130/90
Table 2
Identified SNP genes in the three women with previous GDM
SNP genes Case 1 Case 2 Case 3
Current carbohydrate Normal Glucose Impaired Glucose Type 2 Diabetes
metabolic status Tolerance Tolerance Mellitus
SLC2A2 (rs5393 A/C) Wild type Heterozygous Homozygous Mutant
PCK (rs2071023 C/G) Heterozygous Heterozygous Homozygous Mutant
FTO (rs9939609 A/T) Heterozygous Heterozygous Homozygous Mutant
CDKAL1 (rs10946398 A/C) Homozygous Mutant Heterozygous Homozygous Mutant
122 S. Abou-Hussein et al. / Genetic risk factors for T2DM
4. Discussion
The ability to identify individuals at high risk of developing significant disease conditions has an
important public health import since this would provide a means of introducing lifestyle and medical inter-
ventions early enough to prevent significant disease progression. Ideally a screening test should be simple,
inexpensive, non-invasive, detects all or most of the patients having the disease in question and does not
mistakenly detect too high a proportion of normal subjects, subjecting them to intervention unnecessarily.
The use of clinical risk factors to determine risk of developing gestational and T2DM in the Maltese as
well as in other populations has been previously investigated [1, 4–8]. In the Maltese female population,
a relationship to increased risk of developing severe gestational diabetes has been noted for a maternal age
greater than 35 years [RR 2.8; specificity 86.4%; sensitivity 38.7%], obesity [RR 3.0; specificity 93.6%;
sensitivity 18.9%], previous multiparity [RR 4.1; specificity 97.0%; sensitivity 12.4%] with a history of
macrosomia [RR 1.7; specificity 86.7%; sensitivity 25.5%] [1, 4–6]. Observed predictive factors related
to an increased risk of developing IGT/T2DM in the Maltese population included a previous history of
GDM [RR 5.1; specificity 78.5%; sensitivity 69.6%], age greater than 40 years [RR 2.3; specificity 76.3%;
sensitivity 47.8%], obesity [RR 3.1; specificity 77.4%; sensitivity 56.5%], and the association of hyper-
tension [RR 3.1; specificity 93.5%; sensitivity 26.1%] [5, 7]. These clinically-based risk factors have thus
been shown to be useful in identifying those patients who may be truly disease free, but are not sufficiently
useful when used in isolation to reliably identify those patients who eventually develop diabetes.
The cases described herein illustrate that whereas the clinical picture of all three cases seems approxi-
mately identical, except for the degree of obesity, the rate and severity of development of carbohydrate
intolerance had varied considerably. It thus appears that the presence of clinical risk factors alone is not
sufficiently sensitive to predict the eventual development of diabetes or its rate of development. While
all three cases may eventually develop a diabetic state, the rate of development has obviously progressed
differently. A more accurate method of risk determination would ensure that restricted health services
are timely targeted to those really at risk.
The observations based on the cases described herein confirm that testing for identified alleles can be an
added resource to help those individuals at high risk of developing diabetes early. The woman with a high
profile of homozygous mutations of specific SNPS appeared to be a greater risk of developing T2DM
than her counterparts who were shown to have either; heterozygous or wild genotypes only. Alternatively,
the woman with homozygous mutations of these specific SNPs of specific genes may have developed
the disease at a faster rate than her counterparts. The true relevance of these reported observations needs
to be investigated by formal directed population studies that aim to assess the specificity and sensitivity
of using the SNP markers alone and/or in combination with the known clinically-based risk factors.
The interplay between the genetic variations also is important factor to trace, as in this study; SLC2A2
(rs5393 A/C) was the most influential when correlated with the development of diabetes, especially when
it is associated with a positive family history and obesity, whereas CDKAL1 (rs10946398 A/C) was the
least influential. Glucose transporter 2 isoform is an integral plasma membrane glycoprotein of the liver,
islet beta cells, intestine, and kidney epithelium. SLC2A2 is a Facilitative Glucose Transporter that is
likely to mediate the bidirectional transfer of glucose across the plasma membrane of hepatocytes and
is responsible for uptake of glucose by the beta cells because of its low affinity for glucose. It has been
suggested that it may comprise part of the glucose-sensing mechanism of the pancreatic beta cell [3].
Since the influence of genetic contributors appears to vary from one ethnic population to another, the
relevance of specific SNPs used as risk factors needs to be investigated on a broader scale before being
assumed to be of general rather than local usefulness.
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5. Conclusions
It thus appears that the added use of the specific allele-scoring in women identified at risk on the basis
of their clinical status can be used to further quantify the risk of developing T2DM. This supports other
studies which have suggested that knowledge of common genetic variation appropriately reclassifies
younger but not older people for type 2 diabetes risk beyond clinical risk factors [9]. Further studies
are however necessary on a larger set of the population to confirm the significance of the reported
observation. The effective identification of patients at risk of eventually developing diabetes allows for
directed resource availability to individuals who really will benefit from the intervention.
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